Short Interest in ImmuCell Corporation (NASDAQ:ICCC) Decreases By 35.4%

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) was the target of a large decrease in short interest during the month of July. As of July 31st, there was short interest totaling 12,400 shares, adecreaseof35.4% from the July 15th total of 19,200 shares. Approximately0.2% of the company's stock are short sold. Based on an average daily trading volume, of 27,000 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily trading volume, of 27,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately0.2% of the company's stock are short sold.

Institutional Investors Weigh In On ImmuCell

Large investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock worth $500,000 after acquiring an additional 2,907 shares during the last quarter. Citadel Advisors LLC purchased a new stake in ImmuCell in the 4th quarter worth about $149,000. Northern Trust Corp increased its holdings in ImmuCell by 51.0% in the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 14,982 shares during the last quarter. Finally, Dauntless Investment Group LLC purchased a new stake in ImmuCell in the 4th quarter worth about $676,000. 13.47% of the stock is owned by hedge funds and other institutional investors.

ImmuCell Stock Up 1.8%

NASDAQ ICCC traded up $0.11 on Friday, reaching $6.09. The company had a trading volume of 4,414 shares, compared to its average volume of 11,066. The stock has a market capitalization of $55.11 million, a P/E ratio of 32.05 and a beta of 0.30. The company's fifty day moving average is $6.50 and its 200 day moving average is $5.79. ImmuCell has a 52-week low of $3.34 and a 52-week high of $7.60. The company has a quick ratio of 2.21, a current ratio of 3.85 and a debt-to-equity ratio of 0.28.

ImmuCell (NASDAQ:ICCC - Get Free Report) last announced its earnings results on Thursday, August 14th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.The firm had revenue of $6.45 million during the quarter.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.